Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncolo ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...
Investigator sought to determine whether nelfinavir mesylate plus chemoradiation and image-guided brachytherapy could improve disease-free survival for patients with stage III cervical cancer.
DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates ...
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...
The CEO of Larian Studios confirmed that the announcement of Divinity at The Game Awards 2025 boosted sales of Baldur's Gate 3 and Divinity: Original Sin 2.
Separating user data removed hidden bottlenecks choking my system drive.
EU recommends approval of AstraZeneca’s Imfinzi perioperative regimen for patients with early gastric and gastroesophageal cancers ...
The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual disease (MRD) and complete response (CR) as primary end points in clinical ...
Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% ...
The FDA draft guidance recommends MRD and CR as endpoints for accelerated drug approval in multiple myeloma, emphasizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results